Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study

J. P. Krischer, A. H. Ragab, L. Kun, T. H. Kim, J. P. Laurent, J. M. Boyett, C. J. Cornell, M. Link, A. R. Luthy, B. Camitta

Research output: Contribution to journalArticlepeer-review

86 Scopus citations

Abstract

In a randomized postoperative trial, adjuvant post-irradiation chemotherapy, consisting of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP), was tested versus radiation therapy alone for newly diagnosed medulloblastoma in patients between 1 and 21 years of age. Patients treated with irradiation plus MOPP had a statistically significant increase in overall survival rate at 5 years posttreatment compared to patients treated with radiation therapy alone (74% vs. 56%; p = 0.06, adjusted for race and gender). Although the overall study failed to show a statistically significant advantage for irradiation plus MOPP in event-free survival (p = 0.18), statistical significance was attained in children 5 years of age or older (p = 0.05). More severe hematological toxicities occurred in the group with irradiation plus MOPP; however, this hematotoxicity appeared to be tolerable and acceptable. These results suggest that patients may benefit from combined irradiation and chemotherapy following surgery for medulloblastoma.

Original languageEnglish (US)
Pages (from-to)905-909
Number of pages5
JournalJournal of neurosurgery
Volume74
Issue number6
DOIs
StatePublished - 1991

Keywords

  • chemotherapy
  • medulloblastoma
  • outcome
  • radiation therapy

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A pediatric oncology group study'. Together they form a unique fingerprint.

Cite this